Tests oral DT120 against placebo in adults with major depressive disorder
Compares oral DT120 with placebo in adults with major depressive disorder.
Plain-language title generated from the registry record
Registry title: A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
Key facts
- Where
- Atlanta, Austin, Bennington, Boston, Chicago, Decatur, Denver, Draper, Jacksonville, Las Vegas, Little Rock, Maitland, New York, North Charleston, Orange, Orem, Orlando, Philadelphia, San Diego, Santa Monica, Savannah, Seattle, St Louis, Tampa, and Worcester, United StatesSee the 26 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 74 years old?
Source: NCT07592689, who can take part
Where in United States
- CenExel - Atlanta Center for Medical ResearchAtlanta, United StatesTaking people
- Austin Clinical Trial PartnersAustin, United StatesTaking people
- Memory Clinic, Inc.Bennington, United StatesTaking people
- Adams Clinical WatertownBoston, United StatesTaking people
- Adams Clinical BostonBoston, United StatesNo longer taking part
- Uptown Research InstituteChicago, United StatesTaking people
- CenExel - iResearch AtlantaDecatur, United StatesTaking people
- Mountain View Clinical Research, IncDenver, United StatesTaking people
- Cedar Clinical ResearchDraper, United StatesTaking people
- Clinical Neuroscience Solutions, LLC (Jacksonville)Jacksonville, United StatesTaking people
- Redbird ResearchLas Vegas, United StatesTaking people
- Preferred Research Partners, IncLittle Rock, United StatesTaking people
- K2 Medical Research - MaitlandMaitland, United StatesTaking people
- Adams Clinical HarlemNew York, United StatesNo longer taking part
- Coastal Carolina ResearchNorth Charleston, United StatesTaking people
- ATP Clinical Research Orange CountyOrange, United StatesTaking people
- Inner Space ResearchOrem, United StatesTaking people
- Clinical Neuroscience Solutions, LLC (Orlando)Orlando, United StatesTaking people
- Adams Clinical PhiladelphiaPhiladelphia, United StatesTaking people
- Kadima Neuropsychiatry InstituteSan Diego, United StatesTaking people
- Psychedelic Science InstituteSanta Monica, United StatesTaking people
- Cenexel Iresearch - SavannahSavannah, United StatesTaking people
- Seattle Neuropsychiatric Treatment CenterSeattle, United StatesNot yet recruiting
- Arch Clinical Trials, LLCSt Louis, United StatesTaking people
- K2 Medical Research - TampaTampa, United StatesTaking people
- Vitalix ClinicalWorcester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Definium Therapeutics US, Inc.
- Trial code
- NCT07592689
- Record updated
- 9 November 2026
- Original description
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - AscendRead full original descriptionShow less
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Major Depressive Disorder - Ascend
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend
Inclusion: Diagnosis of MDD per DSM-5; Male or female aged 18 to 74; Currently experiencing a major depressive episode (MDE) of ≥8 weeks and ≤24 months duration; MADRS Total Score ≥26; CGI-S Score ≥4.
Exclusion: Certain psychiatric disorders (other than major depressive disorder); First degree relative with or lifetime history of a psychotic disorder or bipolar disorder; Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine; Any clinically significant unstable illness.